| Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-naïve SB5 … LAAP Derikx, HW Dolby, N Plevris, L Lucaciu, CS Rees, M Lyons, ... Journal of Crohn's and Colitis 15 (12), 2011-2021, 2021 | 24* | 2021 |
| Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis LA Lucaciu, N Constantine-Cooke, N Plevris, S Siakavellas, LAAP Derikx, ... Therapeutic Advances in Gastroenterology 14, 17562848211064004, 2021 | 19 | 2021 |
| Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort B Gros, N Plevris, N Constantine‐Cooke, M Lyons, C O'Hare, C Noble, ... United European Gastroenterology Journal 11 (2), 179-188, 2023 | 7 | 2023 |
| Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis M Lyons, LAAP Derikx, J Fulforth, S McCall, N Plevris, PW Jenkinson, ... Alimentary Pharmacology & Therapeutics 56 (1), 67-76, 2022 | 7 | 2022 |
| A review on statistical and machine learning competing risks methods K Monterrubio‐Gómez, N Constantine‐Cooke, CA Vallejos Biometrical Journal 66 (2), 2300060, 2024 | 2* | 2024 |
| Real-World Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis B Gros, M Goodall, N Plevris, N Constantine-Cooke, AT Elford, C O’Hare, ... Journal of Crohn's and Colitis, jjad187, 2023 | 2 | 2023 |
| Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease N Constantine-Cooke, K Monterrubio-Gómez, N Plevris, LAAP Derikx, ... Clinical Gastroenterology and Hepatology 21 (11), 2918-2927. e6, 2023 | 2 | 2023 |
| Rates, predictive factors and effectiveness of ustekinumab intensification to 4-or 6-weekly intervals in Crohn's disease LAAP Derikx, N Plevris, S Su, B Gros, M Lyons, SI Siakavellas, ... Digestive and Liver Disease 55 (8), 1034-1041, 2023 | 1 | 2023 |
| P489 Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study P Jenkinson, N Plevris, M Lyons, B Gros, L Derikx, N Constantine-Cooke, ... Journal of Crohn's and Colitis 16 (Supplement_1), i455-i456, 2022 | 1 | 2022 |
| P117 Patient perceptions about causes of flare in IBD: results from the baseline dataset of the PREdiCCt study S Siakavellas, L Derikx, L Derr, L Williams, N Plevris, P Jenkinson, ... Journal of Crohn's and Colitis 15 (Supplement_1), S209-S209, 2021 | 1 | 2021 |
| P330 Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD L Derikx, H Dolby, N Plevris, L Lucaciu, C Rees, M Lyons, S Siakavellas, ... Journal of Crohn's and Colitis 15 (Supplement_1), S353-S354, 2021 | 1 | 2021 |
| Real-world effectiveness of upadacitinib in Crohn’s disease: a UK multicentre retrospective cohort study AT Elford, M Bishara, N Plevris, B Gros, N Constantine-Cooke, ... Frontline Gastroenterology, 2024 | | 2024 |
| P823 Real-world effectiveness of upadacitinib in Crohn's disease; a UK multicentre retrospective cohort study A Elford, M Bishara, N Plevris, B Gros, N Constantine-Cooke, J Goodhand, ... Journal of Crohn's and Colitis 18 (Supplement_1), i1533-i1535, 2024 | | 2024 |
| P860 Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis-a six-year follow-up study B Gros, H Ross, M Nwabueze, N Constantine-Cooke, LA Derikx, M Lyons, ... Journal of Crohn's and Colitis 18 (Supplement_1), i1592-i1594, 2024 | | 2024 |
| DOP17 Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison B Gros, N Constantine-Cooke, J Kennedy, AT Elford, C O’Hare, C Noble, ... Journal of Crohn's and Colitis 18 (Supplement_1), i102-i103, 2024 | | 2024 |
| 477c HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY CW Lees, B Gros, JA Kyle, N Plevris, L Derikx, N Constantine-Cooke, ... Gastroenterology 164 (6), S-1571, 2023 | | 2023 |
| 476 MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD INFLAMMATORY BOWEL DISEASE COHORT B Gros, N Plevris, N Constantine-Cooke, M Lyons, C O'Hare, CL Noble, ... Gastroenterology 164 (6), S-95, 2023 | | 2023 |
| Mo1764 INFLAMMATORY BOWEL DISEASE SUBGROUPS IDENTIFIED BY LONGITUDINAL FAECAL CALPROTECTIN PROFILES: A 10-YEAR RETROSPECTIVE ANALYSIS OF THE LOTHIAN IBD REGISTRY N Constantine-Cooke, K Monterrubio-Gómez, N Plevris, L Derikx, ... Gastroenterology 164 (6), S-899, 2023 | | 2023 |
| Mo1783 SURGERY AND BIOLOGIC PRESCRIPTION RATES FOR CROHN'S DISEASE IN LOTHIAN, SCOTLAND; AN UDATED POPULATION BASED COHORT STUDY OVER 17 YEARS P Jenkinson, N Plevris, M Lyons, B Gros, L Derikx, N Constantine-Cooke, ... Gastroenterology 164 (6), S-909, 2023 | | 2023 |
| Mo1782 ANALYSIS OF COLECTOMY RATES AND ADVANCED THERAPY PRESCRIBING FOR ULCERATIVE COLITIS IN LOTHIAN, SCOTLAND; AN UPDATED POPULATION BASED COHORT STUDY P Jenkinson, B Gros, N Plevris, M Lyons, L Derikx, N Constantine-Cooke, ... Gastroenterology 164 (6), S-908, 2023 | | 2023 |
Charlie LeesUniversity of EdinburghVerified email at ed.ac.uk
